HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Clinical trial NCT07612007 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07612007
Sponsor: Mayo Clinic
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Colorectal Carcinoma Metastatic Malignant Neoplasm in the Liver Resectable Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8

Start date: 2026-09-01
Primary completion: 2028-08-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.